Skip to content

Advertisement

  • Poster presentation
  • Open Access

P56 - Control of allergic inflammation and erythrocytes magnesium level in children with bronchial asthma

  • 1,
  • 1 and
  • 1
Clinical and Translational Allergy20144 (Suppl 1) :P111

https://doi.org/10.1186/2045-7022-4-S1-P111

  • Published:

Keywords

  • Nitric Oxide
  • Asthma
  • Asthma Control
  • Magnesium Content
  • Magnesium Level

Purpose

To examine the relationship of severity and duration of allergic inflammation to the erythrocytes magnesium level in children with bronchial asthma (BA).

Materials and methods

40 patients with a diagnosis of mild to moderate severity were divided into 2 groups: Group 1 included 20 patients experienced disease less than 5 years; Group 2 included 20 patients with disease duration of more than 5 years. All patients received standard treatment of inhaled corticosteroids. Patients were to determine the level of NO in exhaled air using a device NObreath and the concentration of markers - sICAM-1, IL-4, IL-8, IFN-gamma, and magnesium content in erythrocytes. To assess the level of asthma control were used ACT test.

Results

Patients comparison groups had comparable levels of clinical control of asthma by AST-test. In determining the level of nitric oxide in exhaled air were obtained pre-credibility of the differences between the groups. A more pronounced level of allergic inflammation in patients 2 groups confirmed higher concentrations of its laboratory markers. In determining the level of magnesium in red blood cells have lower it with the content of the group 2 patients.

Conclusions

The study revealed the discrepancy between clinical asthma control level and laboratory markers of allergic inflammation. In patients with longer experience of the disease on a background of basic therapy revealed higher levels of allergic inflammation and lower levels of magnesium in erythrocytes. Pharmacological correction of magnesium levels may be useful to improve the efficiency of basic therapy of asthma and achieve control of allergic inflammation.

Authors’ Affiliations

(1)
Clinical Pharmacology and Intensive Therapy Department, Volgograd State Medical University, Volgograd, Russia

Copyright

© Shishimorov et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement